Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Gains from Sales and Divestitures (2016 - 2025)

Pediatrix Medical (MD) has disclosed Gains from Sales and Divestitures for 13 consecutive years, with $841425.0 as the latest value for Q4 2025.

  • Quarterly Gains from Sales and Divestitures fell 14.8% to $841425.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $841425.0 through Dec 2025, down 14.8% year-over-year, with the annual reading at $841425.0 for FY2025, 14.8% down from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $841425.0 at Pediatrix Medical, down from $987593.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $987593.0 in Q4 2024, with the low at $418756.0 in Q4 2023.
  • Average Gains from Sales and Divestitures over 5 years is $745246.8, with a median of $748410.0 recorded in 2021.
  • The sharpest move saw Gains from Sales and Divestitures crashed 42.64% in 2023, then surged 135.84% in 2024.
  • Over 5 years, Gains from Sales and Divestitures stood at $748410.0 in 2021, then decreased by 2.45% to $730050.0 in 2022, then plummeted by 42.64% to $418756.0 in 2023, then soared by 135.84% to $987593.0 in 2024, then fell by 14.8% to $841425.0 in 2025.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $841425.0, $987593.0, and $418756.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.